Berbamine is also known to be an ATP-competitive inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII), and it inhibits CaMKII to destabilize c-Myc, an oncoprotein, thereby reducing tumor burden [73,74]. The gene discussed is MYC; the disease is neoplasm.